LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

Search

Martin Marietta Materials Inc

Closed

SectorBasic materials

578.59 3.31

Overview

Share price change

24h

Current

Min

550

Max

587.45

Key metrics

By Trading Economics

Income

-135M

279M

Sales

-312M

1.5B

P/E

Sector Avg

35.843

34.302

EPS

4.62

Dividend yield

0.56

Profit margin

18.188

Employees

9,600

EBITDA

-29M

493M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+26.14% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.56%

2.86%

Next Earnings

29 kwi 2026

Next Dividend date

31 mar 2026

Next Ex Dividend date

1 cze 2026

Market Stats

By TradingEconomics

Market Cap

-6.7B

35B

Previous open

575.28

Previous close

578.59

News Sentiment

By Acuity

73%

27%

145 / 151 Ranking in Basic materials

Technical Score

By Trading Central

Confidence

Bullish Evidence

Martin Marietta Materials Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk
Earnings
Major News Events

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Martin Marietta Materials Inc Forecast

Price Target

By TipRanks

26.14% upside

12 Months Forecast

Average 707.23 USD  26.14%

High 804 USD

Low 612 USD

Based on 15 Wall Street analysts offering 12 month price targets forMartin Marietta Materials Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

8

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

533.69 / 542.19Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

145 / 151 Ranking in Basic materials

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Martin Marietta Materials Inc

Martin Marietta Materials, Inc., a natural resource-based building materials company, supplies aggregates and heavy-side building materials to the construction industry in the United States and internationally. It offers crushed stone, sand, and gravel products; ready mixed concrete and asphalt; paving products and services; and Portland and specialty cement for use in the infrastructure projects, and nonresidential and residential construction markets, as well as in the railroad, agricultural, utility, and environmental industries. The company also produces magnesia-based chemicals products; dolomitic lime primarily to customers for steel production and soil stabilization; and cement treated materials. Its chemical products are used in flame retardants, wastewater treatment, pulp and paper production, and other environmental applications. The company was founded in 1939 and is headquartered in Raleigh, North Carolina.
help-icon Live chat